Finally, we treated CRC-susceptible miR-146a−/− mice with either TRAF6 inhibitor or RIPK2 inhibitor alone, or in combination during AOM/DSS-induced CRC (Fig. 6r, s). This evidence concerns the gene RIPK2 and colorectal carcinoma.